永无止境

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

二 |     新华社北京8月21日电 题：十四届全国人大常委会第二十四次会议有关法律案前瞻          　　新华社记者孙鹏程、刘硕          　　十四届全国人大常委会第二十四次会议将于8月25日至28日在北京举行。         　　充实医疗保障基金管理有关规定、加强高标准农田建设、强化银行业消费者权益保护、加强水资源保护与节约利用、审议道路交通安全法修订草案和反跨境腐败法草案……8月21日，全国人大常委会法制工作委员会发言人黄海华就本次常委会会议拟审议的法律案有关情况进行介绍。                        　　医疗保障法草案三审稿加强医保基金管理使用          　　医疗保障基金是老百姓的看病钱、救命钱，社会关注度很高。         　　“草案三审稿积极回应各方意见，规定国务院医疗保障行政部门在组织制定基本医疗保险基金支付范围、组织开展循证医学和经济性评价时，除了征求有关部门意见外，还应当听取医疗机构、药品经营单位、相关企业、专家和参保人员的意见。”黄海华介绍。         　　草案三审稿还对建立和完善药品、医用耗材集中采购制度，实行多元复合式医疗保险支付方式，优化异地就医直接结算服务等作了规定。         　　耕地保护和质量提升法立法强化高标准农田建设          　　建设高标准农田，是巩固和提高粮食生产能力、保障国家粮食安全的关键举措。党的二十大报告指出，逐步把永久基本农田全部建成高标准农田。

三 |          　　黄海华说，耕地保护和质量提升法草案三审稿完善高标准农田立项、建设、验收、管护机制，健全高标准农田建设工程全周期责任倒查和终身追责机制。“对侵占、损毁高标准农田工程设施或者危害农田设施安全等违法行为，还设定了相应的法律责任。

四 | ”          　　对沙化、风蚀、水蚀耕地开展综合治理，保护黑土地的优良生产能力，明确国家健全粮食主产区利益补偿机制……草案三审稿多处新增规定，聚焦粮食安全这一“国之大者”，强化耕地保护。         　　银行业监督管理法修订压实监督管理机构职责          　　银行业监督管理法修订草案2025年12月提请全国人大常委会初次审议。黄海华介绍，此次二次审议稿增加规定“提高金融服务实体经济质效”的立法目的，与金融法草案做好衔接，并规定对银行业金融机构实施分类分级监督管理等。         　　近年来，发生了银行业金融机构从业人员挪用客户资金等违法行为，社会各界高度关注，希望进一步完善消费者权益保护制度。         　　发言人说，修订草案二审稿回应社会关切，增加规定银行业金融机构及其从业人员不得通过挪用资金等方式侵害存款人和其他客户合法权益。从业人员违反规定造成存款人和其他客户损害的，银行业金融机构应当承担民事责任。         　　水法修订草案二审稿与生态环境法典做好衔接          　　水润民心，泽被万物。8月15日起施行的生态环境法典对水污染防治、水生态保护均有明确规定。此次水法修订，既增加了加快构建国家水网，统筹水资源、水环境、水生态、水灾害治理等规定，也注重与法典做好衔接。         　　建立健全水功能区划、饮用水水源地保护、地下水管理和保护，明确开发利用水资源应当保障基本生态用水……草案二审稿对法典规定的涉水生态保护基本制度作出了具体规定。         　　“草案二审稿还对法典规定的水资源配置和节约使用等进行了细化完善，确定了用水总量控制和定额管理相结合、水资源差别化管控等制度措施。”黄海华说。【编辑:王琴】。

Current article:http://www.lichuorenrenyitankanmeimu.cfd/jaz/20260826/949545.html

Published on:04:45:56